Veille Pharma
Follow
19.6K views | +0 today
Veille Pharma
Responsable des études chez VIGIEPHARMA. Mes posts n'engagent que moi. http://www.vigiepharma.fr/
Your new post is loading...
Your new post is loading...
Scooped by Alexandre DUBOIS
Scoop.it!

In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the meth...

Objective To investigate the 2-year clinical and radiological outcomes of patients with early rheumatoid arthritis (RA; symptom duration <1 year) who had initially responded well to methotrexate monotherapy.


more...
No comment yet.
Scooped by Alexandre DUBOIS
Scoop.it!

Johnson & Johnson issued FDA complete response letter over expanded approval of Simponi | FirstWord Pharma

Johnson & Johnson issued FDA complete response letter over expanded approval of Simponi | FirstWord Pharma | Veille Pharma | Scoop.it
Johnson & Johnson's Janssen Biotech unit announced Friday the receipt of a complete response letter from US regulators regarding the company's filing for expanded approval of Simponi (golimumab) for limiting the progression of structural damage in patients with moderately to severely active rheumatoid arthritis.
more...
No comment yet.